ATI-Betamethasone - templates PDF

Preview

Summary

templates...

Description

ACTIVE LEARNING TEMPLATE:

Medication

STUDENT NAME _____________________________________

Betamethasone MEDICATION __________________________________________________________________________

REVIEW MODULE CHAPTER ___________

CATEGORY CLASS Corticosteroid ______________________________________________________________________

PURPOSE OF MEDICATION

Expected Pharmacological Action Synthetic, long-acting glucocorticoid with minor mineralocorticoid properties but strong immunosuppressive, antiinflammatory, and metabolic actions.

Therapeutic Use Prevention of neonatal respiratory distress syndrome (hyaline membrane disease).

Complications Hypersensitivity or anaphylactoid reactions; aggravation or masking of infections; malaise, weight gain, obesity. Mo adverse effects are dose and treatment duration dependent. CNS: Vertigo, headache, nystagmus, ataxia (rare), increased intracranial pressure with papilledema (usually after discontinuation of medication), mental disturbances, aggravation of preexisting psychiatric conditions, insomnia. CV: Hypertension; syncopal episodes, thrombophlebitis, thromboembolism or fat embolism, palpitation, tachycardia, necrotizing angiitis; CHF. Endocrine: Suppressed linear growth in children, decreased glucose tolerance; hyperglycemia, manifestations of latent diabetes mellitus; hypocorticism; amenorrhea and other menstrual difficulties.

Medication Administration Respiratory Distress Syndrome Adult: IM 2 mL of sodium phosphate to mother once daily 2– 3 d before delivery

Contraindications/Precautions In patients with systemic fungal infections. Use caution with Ocular herpes simplex; concomitant use of aspirin; osteoporosis; diverticulitis, nonspecific ulcerative colitis, abscess or other pyrogenic infection, peptic ulcer disease; hypertension; renal insufficiency; myasthenia gravis.

Interactions Barbituates, phenytoin, rifampin may reduce pharmacologic effect of betamethasone by increasing its metabolism.

Nursing Interventions Assess therapeutic effectiveness. Response following intraarticular, intralesional, or intrasynovial administration occurs within a few hours and persists for 1– 4 wk. Following IM administration response occurs in 2– 3 h and persists for 3– 7 d.

Client Education Evaluation of Medication Effectiveness Child will not experience respiratory insuffecency when born.

ACTIVE LEARNING TEMPLATES

Monitor weight at least weekly. Discontinue slowly after systemic use of 1 wk. Abrupt withdrawal, especially following high doses or prolonged use, can cause dizziness, nausea, vomiting, fever, muscle and joint pain, weakness. Do not breast feed while taking this drug.

THERAPEUTIC PROCEDURE

A7...